{{Rsnum
|rsid=803917
|Gene=ASTN2
|Chromosome=9
|position=116705381
|Orientation=minus
|GMAF=0.2916
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ASTN2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 7.2 | 39.6 | 53.2
| HCB | 2.2 | 15.6 | 82.2
| JPT | 3.6 | 19.8 | 76.6
| YRI | 32.6 | 46.1 | 21.3
| ASW | 7.0 | 54.4 | 38.6
| CHB | 2.2 | 15.6 | 82.2
| CHD | 1.9 | 28.0 | 70.1
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 11.0 | 52.0 | 37.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs803917
|Name_s=
|Gene_s=ASTN2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00009. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109323
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs803917
|overall_frequency_n=79
|overall_frequency_d=126
|overall_frequency=0.626984
|n_genomes=44
|n_genomes_annotated=0
|n_haplomes=65
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}